The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL).
S. M. Horwitz
Consultant or Advisory Role - Celgene
Stock Ownership - Celgene
Honoraria - Celgene
B. Coiffier
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
F. M. Foss
Consultant or Advisory Role - Celgene; Eisai
Honoraria - Allos Therapeutics; Cephalon; Eisai; Merck
H. M. Prince
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
L. Sokol
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Gloucester Pharmaceuticals
M. Greenwood
No relevant relationships to disclose
D. Caballero
No relevant relationships to disclose
P. Borchmann
No relevant relationships to disclose
F. Morschhauser
Honoraria - Celgene
M. Wilhelm
No relevant relationships to disclose
L. C. Pinter-Brown
No relevant relationships to disclose
S. Padmanabhan
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
A. R. Shustov
Honoraria - Celgene
Research Funding - Gloucester Pharmaceuticals
J. Nichols
Employment or Leadership Position - Celgene
J. Balser
No relevant relationships to disclose
S. Carroll
Employment or Leadership Position - Celgene
B. Pro
Research Funding - Celgene